EP1280468A2 - Catheter d'ablation pour irm - Google Patents
Catheter d'ablation pour irmInfo
- Publication number
- EP1280468A2 EP1280468A2 EP01935451A EP01935451A EP1280468A2 EP 1280468 A2 EP1280468 A2 EP 1280468A2 EP 01935451 A EP01935451 A EP 01935451A EP 01935451 A EP01935451 A EP 01935451A EP 1280468 A2 EP1280468 A2 EP 1280468A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- ablation catheter
- shaft
- catheter according
- electrode
- wire
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002679 ablation Methods 0.000 title claims abstract description 118
- 239000000463 material Substances 0.000 claims abstract description 42
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 16
- 239000010949 copper Substances 0.000 claims description 16
- 229910052802 copper Inorganic materials 0.000 claims description 16
- 239000004814 polyurethane Substances 0.000 claims description 16
- 229920002635 polyurethane Polymers 0.000 claims description 16
- 229920004934 Dacron® Polymers 0.000 claims description 11
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 11
- 239000004593 Epoxy Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000004382 potting Methods 0.000 claims description 7
- 229910052790 beryllium Inorganic materials 0.000 claims description 6
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 claims description 6
- 229920003023 plastic Polymers 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 6
- 229910001369 Brass Inorganic materials 0.000 claims description 5
- 229910000881 Cu alloy Inorganic materials 0.000 claims description 5
- 239000010951 brass Substances 0.000 claims description 5
- 229920004738 ULTEM® Polymers 0.000 claims description 4
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 238000001125 extrusion Methods 0.000 claims 8
- 239000010935 stainless steel Substances 0.000 claims 2
- 230000003902 lesion Effects 0.000 description 85
- 238000003384 imaging method Methods 0.000 description 27
- 230000002861 ventricular Effects 0.000 description 25
- 238000002595 magnetic resonance imaging Methods 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 20
- 230000002123 temporal effect Effects 0.000 description 20
- 238000000034 method Methods 0.000 description 17
- 238000013153 catheter ablation Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 230000001746 atrial effect Effects 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 238000007674 radiofrequency ablation Methods 0.000 description 9
- 229910052688 Gadolinium Inorganic materials 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 8
- 230000002452 interceptive effect Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000002594 fluoroscopy Methods 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 239000004809 Teflon Substances 0.000 description 5
- 229920006362 Teflon® Polymers 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000005245 right atrium Anatomy 0.000 description 5
- 210000003484 anatomy Anatomy 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- IZOOGPBRAOKZFK-UHFFFAOYSA-K gadopentetate Chemical compound [Gd+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O IZOOGPBRAOKZFK-UHFFFAOYSA-K 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000003685 thermal hair damage Effects 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- 206010003662 Atrial flutter Diseases 0.000 description 3
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 230000003126 arrythmogenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000013184 cardiac magnetic resonance imaging Methods 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002962 histologic effect Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 210000005241 right ventricle Anatomy 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000006808 Atrioventricular Nodal Reentry Tachycardia Diseases 0.000 description 2
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 206010003668 atrial tachycardia Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000005242 cardiac chamber Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000003754 machining Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- 210000002620 vena cava superior Anatomy 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000026914 Congenital cardiac disease Diseases 0.000 description 1
- 208000033999 Device damage Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 201000008803 Wolff-Parkinson-white syndrome Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003157 atrial septum Anatomy 0.000 description 1
- 230000008276 biophysical mechanism Effects 0.000 description 1
- 231100001012 cardiac lesion Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000005247 right atrial appendage Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000000264 spin echo pulse sequence Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000000591 tricuspid valve Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/0105—Steering means as part of the catheter or advancing means; Markers for positioning
- A61M25/0133—Tip steering devices
- A61M25/0147—Tip steering devices with movable mechanical means, e.g. pull wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/00234—Surgical instruments, devices or methods for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00243—Type of minimally invasive operation cardiac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/00234—Surgical instruments, devices or methods for minimally invasive surgery
- A61B2017/00292—Surgical instruments, devices or methods for minimally invasive surgery mounted on or guided by flexible, e.g. catheter-like, means
- A61B2017/003—Steerable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/0091—Handpieces of the surgical instrument or device
- A61B2018/00916—Handpieces of the surgical instrument or device with means for switching or controlling the main function of the instrument or device
- A61B2018/0094—Types of switches or controllers
- A61B2018/00952—Types of switches or controllers rotatable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
- A61B90/37—Surgical systems with images on a monitor during operation
- A61B2090/374—NMR or MRI
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/0105—Steering means as part of the catheter or advancing means; Markers for positioning
- A61M25/0133—Tip steering devices
- A61M2025/0161—Tip steering devices wherein the distal tips have two or more deflection regions
Definitions
- the distal assembly 34 comprises a core 40 which has a proximal portion 41 adapted to be received in the distal tip 34 of the tipstock 32, and a compressible head 42 at its distal end.
- the compressible head 42 includes anchor tabs 47a, 47b.
- the core 40 has a longitudinal slot 44 extending proximally from its distal face which permits the anchor tabs 47a, 47b to resiliently flex toward each other as the core 40 is received within an aperture 45 in a hollow non-magnetic (e.g. gold) ablation electrode 46 ( Figure 15a).
- the core 40 is preferably made of a nonmagnetic material having a low temperature coefficient, such as the ULTEM ® polyetheraide 1000 resin produced by the GE Plastics division of the General Electric Company, Pittsfield, MA.
- the low temperature coefficient material provides thermal insulation between the ablation electrode 46 and the tipstock 32, and, preferably, the core 40 has a lower thermal mass than the ablation electrode.
- the provision of the core 40 between the tipstock 32 and the ablation electrode 46 reduces the likelihood of catheter damage during an ablation procedure which better ensures that a single catheter can be used for a given procedure, or perhaps reused (once sterilized) in subsequent procedures.
- the cap electrode 46 and the distal tip 34 of the tipstock 32 may be spaced from each other once the core 40 has been mounted in the distal tip 34 by a thin bead of epoxy, or by an annular ring on the core 40, disposed between its proximal end 41 and the compressible head 42. Further, a wider range of materials can be selected for the tipstock 32, including materials with melt-temperatures that are significantly less than the expected ablation temperature, such as polyurethane. With further reference to Figures 14 and 15 A, the distal assembly 34 preferably serves as an anchor for the steering wire 38 and also preferably houses a temperature sensor 54.
- the tipstock 32 is connected to the distal end of the shaft 30 in conventional manner, preferably along complementary tapered and overlapping regions at their distal and proximal ends, respectively, by ultrasonic welding (Figure 15B).
- the assembly of the distal tip assembly 24 is as follows.
- the plastic core 40 is preferably injection molded.
- the ablation electrode 46 is machined to have the desired overall dimension for the size of catheter with which it is to be used.
- the machining is preferably performed under computer control using a machine that can select a first drill bit to generally hollow out the ablation electrode 46, then a second, smaller bit to define the cavity 96, and finally to form the groove 48 using a key cutter, for example, by circular interpolation as understood by those of ordinary skill in the art of machining.
- Conductive wire 52 is preferably wrapped like a lasso and resistance welded to the ablation electrode 46.
- a teflon coated steering wire 38 is selected, the portions of the steering wire 38 that are anchored to the core 40 and the control handle 24 preferably being stripped clear of the teflon. Teflon is difficult to bond and is removed to anchor the exposed steering cable.
- a lubricous sleeve such as teflon may be bonded to the steering wire 38 to reduce the frictional forces that are imparted by the walls of lumens 70, 78 when the steering wire is moved and electrically insulate the steering wire.
- a second steering wire 38A may be threaded through lumens 98 disposed on the opposite side of the central lumen 94.
- the ablation electrode 46 may be filled with a potting compound 102 such as FDA-2 epoxy and the core and ablation electrode snapped together in the manner previously described.
- a potting compound 102 such as FDA-2 epoxy and the core and ablation electrode snapped together in the manner previously described.
- the snap action of the core 40 and ablation electrode 46 is both audible and tactile.
- the steering wire, thermistor wires, and ablation electrode wire are received without any twisting action unlike other known methods of making an ablation catheter.
- the potting compound 102 electrically and thermally isolates the steering wire 38 from the ablation electrode 46.
- Radiofrequency ablation was performed using a standard clinical RF generator (Atakr®, Medtronic, Minneapolis, MN) with open loop control.
- the generator was located outside the scan room and was electrically interfaced to the animal via the above described ablation catheters.
- the dispersive ground electrode consists of a large conductive adhesive pad that is attached to the skin of the animal to complete the circuit.
- Intracardiac electrogram tracings were acquired using the same catheters via a similar 12-channel shielded filter box and were recorded using automated data acquisition software. The effect of the RF ablation signal on image quality is shown in Figure 1.
- the left panel represents an image acquired during RF delivery without filtering while the image on the right shows the same slice during RF delivery with filtering. Note that there is no evidence of noise or artifact and the tip of the catheter is clearly visible in the right ventricular apex (arrow).
- a 7F non-magnetic single electrode ablation catheter was positioned at the inferior lateral wall of the right atrium in three animals to determine the accuracy of catheter localization under MR guidance (no ablation).
- FGRE fast gradient recall echo
- the catheter was imaged to isolate the optimal tomographic slice containing the catheter electrode. After baseline images were acquired for this slice prescription, RF ablation was performed in the right ventricle between the distal electrodes and a large surface area skin patch at a power of 20 W for 60 seconds. To avoid electrode coagulum formation, impedance was monitored by an automatic open-loop feedback system that terminates RF delivery if the impedance exceeds 220 ohms.
- FSE fast spin echo
- the animal was sacrificed by anesthesia overdose and the heart was excised and sectioned through the right ventricular lesion into slices corresponding to the tomographic MR imaging slices. Lesion location, morphology, width, length and transmural extent were determined and recorded at gross examination and right ventricular lesions were photographed and matched with the corresponding T2 and contrast enhanced Tl -weighted lesion images. Sections from thermally damaged tissues were bisected longitudinally and submitted for histologic staining (Masson's trichrome and hematoxylin-eosin).
- Specimens were then analyzed under light microscopy at 40X to characterize global morphologic changes (9) (e.g., delineated cellular junctions and nuclei, and interstitial edema) for determination of the degree of heat induced cellular damage and necrosis.
- global morphologic changes 9 (e.g., delineated cellular junctions and nuclei, and interstitial edema) for determination of the degree of heat induced cellular damage and necrosis.
- lesion signal intensity, length, width and area were measured directly from MR images using an off-line quantitative analysis package (Image Tool, Scion Image, Bethesda, MD). Each parameter was measured 10 times for each time frame from baseline to 20 minutes post-ablation. Mean signal intensity from region of interest (ROI) measurements was then normalized (mean ROI signal intensity at time t divided by the baseline signal intensity) and plotted as a function of time. A similar method was used following gadolinium injection on Tl -weighted imaging. Additionally, IEGMs were analyzed pre and post-ablation for changes in signal amplitude and waveform shape.
- ROI region of interest
- a MR fluoroscopy sequence was used to successfully position the non- steerable catheter at atrial and ventricular target sites in all animals.
- MR catheter placement was attempted to target the inferior lateral wall of the right atrium from a jugular access ( Figure 2). Images were acquired without breath-hold once every heart beat with one-second updates. Details of the right atrial anatomy could be appreciated in all animals as several major endocardia! anatomic landmarks were successfully identified, including the superior and inferior vena cava, atrial septum, right atrial appendage, coronary sinus, eustachian ridge, fossa ovalis and tricuspid valve. The catheter remained in the imaging plane throughout the entire navigation sequence in 2 of 3 animals.
- T I - FGRE images of the same tomographic slice were acquired before and following 7 ml peripheral gadolinium injection ( Figure 5a,b).
- the lesion border was clearly demarcated 60 seconds following contrast injection.
- a lesion profile is simply a plot of signal intensity over a fixed spatial domain passing though the lesion, as illustrated by Figure 7a for a single time frame.
- the three- dimensional surface plot represents a series of these profiles in time, where the z-axis represents the color-coded signal intensity and the x and y-axes represent position and time following RF delivery, respectively.
- the lesion grew dramatically in signal intensity and size from the baseline level shown by the arrow. Maximum signal intensity and lesion area were achieved 12.2 ⁇ 2.1 and 5.3 ⁇ 1.4 minutes following RF delivery, respectively.
- This study concerns a novel MRI-compatible interventional electrophysiology hardware system in conjunction with a newly developed real-time interactive cardiac MRI system to characterize the temporal and spatial development of cardiac lesions following radiofrequency ablation.
- This finding indicate that: 1) MR images and IEGMs can be acquired during radiofrequency ablation therapy using specialized radiofrequency filters; 2) nonmagnetic MR compatible catheters can be successfully placed at right atrial and right ventricular targets using fast MR imaging sequences with interactive scan plane modification; 3) regional changes in ablated cardiac tissue are detectable and can be visualized using FSE and FGRE images; 4) the spatial extent of heat induced necrosis can be accurately quantified by MRI immediately following thermal damage; and 5) lesion transmurality can be assessed. These results may have significant implications for the guidance, delivery, and monitoring of cardiac ablation therapy by interventional MRI.
- MR guided catheter placement Another very important feature of MR guided catheter placement is the ability to visualize the electrode-endocardial tissue interface, which has been shown to increase lesion size by improving the efficiency of RF tissue delivery. While traditional indicators of electrode contact such as fluoroscopic catheter stability and intracardiac electrogram amplitude are useful, these parameters are relatively insensitive indicators of electrode-tissue contact.
- An important limitation of passive MR catheter tracking is the need to manipulate the catheter within the imaging slice (typically 5- 10 mm wide), which may be especially difficult during catheter placement in geometrically complex vessels and cardiac chambers where catheter curvature and loops are common.
- FGRE imaging is preferable to FSE for cardiac ablation therapy since imaging times are decreased significantly and quality images may be acquired without cardiac gating and breath-holds.
- An important parameter for contrast-enhanced lesion imaging is the duration post-ablation for optimal gadolinium uptake, hi this study we injected contrast 30 minutes post-ablation and observed a rapid uptake of gadolinium in the affected area of the myocardium. It is not known, however, how quickly the lesion is capable of contrast uptake. The answer to this question has direct clinical implications and may also lend additional insight into the biophysical mechanisms of in vivo lesion formation.
- MRI guided ablation is not subject to the aforementioned limitations, the technique and system are in the early stages of development and there are number of technical requirements including non-magnetic catheters, monitoring equipment and electromagnetic filtering systems. Additionally, while new advances in scanner hardware have allowed for realtime MR imaging (20 frames/second), passive catheter tracking can be confounded by complex catheter movements that cause the catheter to leave the imaging plane. Lastly, the delayed nature of lesion formation following the initial RTF delivery confounds instantaneous assessment of lesion size.
- the ability to directly visualize the spatial extent of atnial lesions with high spatial resolution may help facilitate the placement of linear transmural atrial lesions and allow for realtime interactive detection and elimination of skip lesions. This potential may have particular importance since it has been shown that ablation lines with skip lesions are not only ineffective but may be arrhythmogenic.
- the ability to characterize the temporal evolution of lesions can be used for therapy titration and avoidance of damage to tissue outside the ablation target volume, although the observed delayed biophysical response of the lesion may confound an instantaneous assessment of lesion size.
- radiofrequency cardiac ablation can be performed under MRI guidance in vivo.
- Catheters are clearly defined and easily positioned in gradient echo images and the spatial and temporal extent of ventricular ablation lesions can be accurately visualized using T2-weighted fast spin echo imaging and Tl - weighted contrast-enhanced fast gradient echo imaging with a standard cardiac phased array thoracic coil.
- lesion size by MRI agrees well with actual postmortem lesion size and high fidelity intracardiac electrophysiologic signals can be acquired and monitored during imaging.
- MRI guided cardiac ablation may be a useful technique that will eliminate ionizing radiation exposure, help provide accurate therapy titration and facilitate the creation of linear, contiguous and transmural lesions, and may lend insight into the physiologic effects of novel ablation techniques and technologies.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Anesthesiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Plasma & Fusion (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Mechanical Engineering (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Surgical Instruments (AREA)
- Materials For Medical Uses (AREA)
Abstract
L'invention concerne un cathéter d'ablation compatible avec des systèmes d'IRM. Ce cathéter comprend une tige et une pointe distale constituées d'un matériau pour IRM, au moins une électrode supportée sur la pointe distale, cette électrode étant constituée d'un matériau pour IRM, et au moins un fil pour IRM relié à l'électrode et se prolongeant à partir de l'électrode vers l'extrémité proximale de la tige, ce film étant constitué d'un matériau pour IRM.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20441900P | 2000-05-12 | 2000-05-12 | |
US204419P | 2000-05-12 | ||
PCT/US2001/015475 WO2001087173A2 (fr) | 2000-05-12 | 2001-05-14 | Catheter d'ablation pour irm |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1280468A2 true EP1280468A2 (fr) | 2003-02-05 |
Family
ID=22757790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01935451A Withdrawn EP1280468A2 (fr) | 2000-05-12 | 2001-05-14 | Catheter d'ablation pour irm |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1280468A2 (fr) |
JP (1) | JP2004511271A (fr) |
WO (1) | WO2001087173A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7306593B2 (en) * | 2002-10-21 | 2007-12-11 | Biosense, Inc. | Prediction and assessment of ablation of cardiac tissue |
CN101001569B (zh) | 2004-02-06 | 2010-05-26 | 韦克福里斯特大学健康科学院 | 评估组织特性和检测病人整体心脏损害的系统 |
WO2007092159A2 (fr) | 2006-02-02 | 2007-08-16 | Wake Forest University Health Sciences | Systèmes de visualisation cardiaque pour afficher des images en 3-d de distributions d'intensité cardiaque de voxels avec des outils de traçage médicaux interactifs de limites |
DE102007035847A1 (de) * | 2007-07-31 | 2009-02-05 | Iprm Intellectual Property Rights Management Ag | Kathetersystem mit optischer Sonde und Verfahren zur Applikation einer optischen Sonde in ein Kathetersystem |
WO2010144405A2 (fr) | 2009-06-08 | 2010-12-16 | Surgivision, Inc. | Systèmes chirurgicaux guidés par irm avec alertes de proximité |
CN102625670B (zh) | 2009-06-16 | 2015-07-15 | 核磁共振成像介入技术有限公司 | Mri导向装置以及能够近实时地跟踪和生成该装置的动态可视化的mri导向的介入系统 |
US12220541B2 (en) | 2019-07-03 | 2025-02-11 | Biosense Webster (Israel) Ltd. | Sensing and mapping catheter for guiding and supporting balloon catheter |
CN112710935B (zh) * | 2021-03-29 | 2021-06-25 | 吉安诺惠诚莘科技有限公司 | 一种电力电线电缆防护层烧蚀状况预报警系统及方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5318025A (en) * | 1992-04-01 | 1994-06-07 | General Electric Company | Tracking system to monitor the position and orientation of a device using multiplexed magnetic resonance detection |
US5383852A (en) * | 1992-12-04 | 1995-01-24 | C. R. Bard, Inc. | Catheter with independent proximal and distal control |
JPH08509141A (ja) * | 1993-04-14 | 1996-10-01 | ファーマサイクリックス,インコーポレイティド | 磁気画像の可視性を強化する医療装器及び材料 |
US5611777A (en) * | 1993-05-14 | 1997-03-18 | C.R. Bard, Inc. | Steerable electrode catheter |
JPH10513098A (ja) * | 1995-11-24 | 1998-12-15 | フィリップス エレクトロニクス エヌ ベー | 介入処置用のmriシステム及びカテーテル |
US5755760A (en) * | 1996-03-11 | 1998-05-26 | Medtronic, Inc. | Deflectable catheter |
US6701176B1 (en) * | 1998-11-04 | 2004-03-02 | Johns Hopkins University School Of Medicine | Magnetic-resonance-guided imaging, electrophysiology, and ablation |
-
2001
- 2001-05-14 WO PCT/US2001/015475 patent/WO2001087173A2/fr not_active Application Discontinuation
- 2001-05-14 EP EP01935451A patent/EP1280468A2/fr not_active Withdrawn
- 2001-05-14 JP JP2001583644A patent/JP2004511271A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO0187173A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001087173A3 (fr) | 2002-03-07 |
JP2004511271A (ja) | 2004-04-15 |
WO2001087173A2 (fr) | 2001-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030208252A1 (en) | Mri ablation catheter | |
US9301705B2 (en) | System and method for magnetic-resonance-guided electrophysiologic and ablation procedures | |
US9259290B2 (en) | MRI-guided surgical systems with proximity alerts | |
US9242090B2 (en) | MRI compatible medical leads | |
US8825133B2 (en) | MRI-guided catheters | |
Lardo | Real-time magnetic resonance imaging: diagnostic and interventional applications | |
WO2001087173A2 (fr) | Catheter d'ablation pour irm | |
AU2007219343C1 (en) | System and method for magnetic-resonance-guided electrophysiologic and ablation procedures | |
Kolandaivelu et al. | MRI Anatomy for Cardiac Mapping and Ablation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20021030 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE CH CY DE DK ES FR GB IT LI |
|
17Q | First examination report despatched |
Effective date: 20050224 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050907 |